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Oedema is a defining element of the nephrotic syndrome. Its’ management varies
considerably between clinicians, with no national or international clinical guidelines, and
hence variable outcomes. Oedema may have serious sequelae such as immobility, skin
breakdown and local or systemic infection. Treatment of nephrotic oedema is often of
limited efficacy, with frequent side-effects and interactions with other pharmacotherapy.
Here, we describe the current paradigms of oedema in nephrosis, including insights
into emerging mechanisms such as the role of the abnormal activation of the epithelial
sodium channel in the collecting duct. We then discuss the physiological basis for
traditional and novel therapies for the treatment of nephrotic oedema. Despite being
the cardinal symptom of nephrosis, few clinical studies guide clinicians to the rational
use of therapy. This is reflected in the scarcity of publications in this field; it is time to
undertake new clinical trials to direct clinical practice.
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INTRODUCTION
Interstitial oedema is present in all individuals with nephrotic syndrome and can be profound,
accounting for as much as an additional 30% to an individual’s total body weight (Doucet et al.,
2007). Oedema is one of the four defining features of the nephrotic syndrome and is the symptom
most commonly requiring intervention (Crew et al., 2004). The other three defining features of
nephrotic syndrome are hypoalbuminemia, hyperlipidemia, and proteinuria.
The prevalence of nephrotic syndrome in a small historical retrospective study from 1996 in
the United States reported that 60% of all renal biopsies were performed to establish a diagnosis
after this presentation (Korbet et al., 1996). It is plausible that this number has not significantly
changed. The incidence of primary glomerulonephritides causing the nephrotic syndrome between
1980 to 2010 (limited to the three most common histological findings: minimal change disease,
membranous nephropathy and focal segmental glomerular sclerosis) in adults was 2.6 per 100,000
per year (McGrogan et al., 2011).
The burden of symptomatic disease is high, mainly with oedema. Parents of oedematous
children report increased anxiety and multiple emergency hospital visits (Beanlands et al., 2017).
Peripheral oedema may be uncomfortable, leading to functional restraint, restricted leg movement,
and impaired mobility (Doucet et al., 2007). Oedema may also cause increased skin tension,
resulting in blistering, skin breakage and exudate extrusion, offering an encouraging environment
for bacterial infection. The risk of infection is exacerbated by ‘nephrotic immunodeficiency’
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caused by the urinary loss of immunoglobulins (Ogi et al.,
1994) and T-cell transformation dysfunction (Fodor et al., 1982).
Further, asymptomatic pulmonary congestion can be present
in active nephrosis (Marino et al., 2016) and there is a strong
association of cardiovascular risk in an overloaded chronic
kidney disease cohort (Hung et al., 2014).
The two main contributors to oedema are the urinary loss of
albumin and excessive sodium. Hence, diuretics are used due to
the known tubular effects on sodium and water reabsorption.
Before we can target and tailor treatment, we first need to
understand the underlying physiology of oedema formation.
OEDEMA FORMATION
There are two paradigms of oedema formation in nephrosis:
the so-called under-fill and over-fill models; it is thought
that these can be present in the same individual at different
times over the course of their disease (Perico and Remuzzi,
1993; Humphreys, 1994). Both result in sodium and water
retention and increased interstitial fluid volume presenting
as oedema. A detailed review of the pathophysiology of
oedema formation is outside the scope of this article, and we
direct readers to recent reviews (Siddall and Radhakrishnan,
2012; Cadnapaphornchai et al., 2014; Ray et al., 2015; Ellis,
2016).
Under-Fill Theory
Hypoalbuminemia reduces the capillary oncotic pressure and
the imbalance of Starling’s forces leads to interstitial leakage of
fluid and decreased circulating volume (Doucet et al., 2007).
The under-fill theory proposes that the decreased circulating
volume leads to renal hypoperfusion and activation of the renin-
angiotensin-aldosterone system (RAAS) (Perico and Remuzzi,
1993). Stimulation causes avid sodium and water reabsorption
(Doucet et al., 2007).
There are data from rat models of nephrosis suggesting that
increased activity of the proximal tubular cell sodium/proton
antiporter NHE3 may contribute to sodium retention, but this
has not been extensively reported (Besse-Eschmann et al., 2002;
Klisic et al., 2003). Furthermore, distal delivery of sodium is the
same in nephrotic and non-nephrotic kidneys (Ichikawa et al.,
1983).
The distal collecting tubule, cortical and outer medullary
collecting ducts are the major sites of sodium reabsorption
under the control of aldosterone (Mernissi and Doucet, 1983).
In nephrosis, cortical collecting ducts demonstrate increased
sodium retention associated with stimulation of basolateral
Na+,K+-ATPase and apical epithelial sodium channel (ENaC)
(Féraille et al., 1993; Deschênes and Doucet, 2000). The
stimulation of Na+,K+-ATPase results from transcriptional
induction of subunits and targeting newly synthesized pumps
to the basolateral membrane where the pumps are able to
reabsorb sodium (Deschênes et al., 2001a). Pre-formed ENaC
is also targeted to the apical membrane via non-transcriptional
mechanisms (Lourdel et al., 2005; de Seigneux et al., 2006; Kim
et al., 2006).
ENaC is a target for aldosterone and is discussed in detail
below. Activation of beta-1 adrenoceptors stimulates renin
secretion, however, there are no published studies implicating
this in nephrotic syndrome. Renal denervation and beta-blocker
therapy are of proven benefit in treating oedema of heart failure
(Byku and Mann, 2017), but propranolol did not induce a diuresis
or natriuresis (Bauer, 1983) suggesting an alternative unexplained
mechanism instead of renin suppression alone.
While the under-fill theory still has considerable support, a
sizable body of evidence supports other paradigms of oedema
formation. If the under-fill theory was solely responsible then
RAAS blockers or restoration of circulating volume would
be curative treatment. Captopril (RAAS blocker) failed to
change urinary sodium excretion despite successful inhibition
of aldosterone secretion (Brown et al., 1984). A proportion
of individuals have elevated renin and aldosterone profiles in
keeping with an under-filled vascular space, yet, many have
suppressed renin and aldosterone activity (Meltzer et al., 1979).
Measuring the plasma volume in nephrotic individuals using
radioactive albumin demonstrated only 2% of the cohort had a
low plasma volume (Geers et al., 1984). Two independent groups
in the 1980s demonstrated that intravenous infusion of atrial
extract or synthetic atrial natriuretic peptide (ANP) resulted in
less than 50% of individuals having a natriuretic and diuretic
response despite volume repletion (Koepke and DiBona, 1987;
Perico et al., 1989). Interestingly, a low serum albumin alone does
not appear to mediate renal sodium retention, as individuals with
congenital an-albuminemia do not develop oedema (Koot et al.,
2004).
One challenge may be identifying the under-filled individual.
A group of Belgian investigators tried to find a clinical test to
actively differentiate between these under- and over-filled cohorts
(Keenswijk et al., 2018). In nephrotic children a high urinary
potassium to urinary potassium and sodium ratio (UrK+/UrK+
+ UrNa+), suggesting secondary hyperaldosteronism, can be a
useful test to identify under-filled children that may benefit from
intravenous therapy (Keenswijk et al., 2018).
Over-Fill Theory
The over-fill theory states that RAAS activation and imbalance
in Starling’s forces across the capillaries are an insufficient
mechanism to produce oedema and instead, changes in the
capillary endothelial filtration barrier are responsible (Doucet
et al., 2007).
Capillary Permeability
Capillary permeability is important in determining distribution
of fluid between vascular and interstitial compartments.
Changes in the capillary basement membrane akin to
aging exist in nephrotic syndrome, with thickening of
the basement membrane, altered protein composition
and increased stiffness; the thickening of the basement
membrane increases protein permeability (Kottke and Walters,
2016).
Nephrotic patients had higher calf capillary filtration capacity
without evidence of capillary hypertension suggesting that
the functional capillary surface area available for exchange is
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increased in nephrotic syndrome (Lewis et al., 1998). The
capillary filtration capacity is increased almost twofold in
nephrotic individuals (Ellis, 2016).
Studies in nephrotic rats have demonstrated defective
capillary basement membrane permeability by ferritin
accumulation (Farquhar and Palade, 1961). Vascular permeability
is increased in guinea pigs when injected with human lymphocyte
supernatants from nephrotic patients but not healthy controls
(Lagrue et al., 1975b). A permeability increasing factor (such as
a circulating lymphokine) was proposed to affect the vasculature
irrespective of the albumin or sodium (Lagrue et al., 1975b). It
was hypothesized that this permeability factor was a protein that
activates the kinin system (Lagrue et al., 1975a). Initial interest
in bradykinin was supported by elevated bradykinin levels in
abdominal transudates from nephrotic patients (Paskhina et al.,
1979) but no further evidence has been published.
The role for vascular hyperpermeability was further
demonstrated using technetium labeled albumin in nephrotic
human patients and healthy controls (Rostoker et al., 2000).
Nephrotic patients had high levels of hyperpermeability
which was reversible with steroids and bilbao extract (which
reduces capillary permeability) and the authors proposed
a vascular permeability factor derived from local immune
cells (Rostoker et al., 2000). The search for the permeability
factor remains elusive although possible targets are being
proposed such as cytokine receptor-like factor 1 with
specific therapeutic targets (Savin et al., 2017). Vascular
endothelial growth factors (VEGF) are regulators of capillary
permeability (Bates, 2010). However, circulating VEGF
levels are not different in nephrotic and non-nephrotic
children, and rat VEGF expression is not altered, nor does
administration of VEGF induce nephrosis (Webb et al.,
1999).
Nephrotic ascites (peritoneal fluid accumulation) is likely
to develop via similar mechanisms as nephrotic interstitial
fluid (Udwan et al., 2016). In nephrotic rats there is a change
in capillary permeability with an increased water filtration
coefficient in both paracellular and transcellular pathways,
with a reduction in the coefficient for proteins (Udwan
et al., 2016). This is associated with greater expression of
aquaporin-1 (AQP1) in the parietal peritoneum (Udwan
et al., 2016). Water permeability is reversible by inhibiting
NF-κB and N-acetylcysteine (Udwan et al., 2016). When
both are inhibited, the volume of ascites is reduced by 60%
suggesting that this water filtration coefficient, possibly
mediated by AQP1, is important in ascites formation in these
nephrotic animals (Udwan et al., 2016). The association with
aquaporin dysregulation has also been demonstrated in nephrotic
human kidneys. A study of 54 primary nephrotic individuals
determined aquaporin expression by immunohistochemistry
in renal biopsy tissue and measured urinary aquaporin.
In nephrotics, AQP1 expression was significantly reduced
in renal tissue whereas aquaporin-2 (AQP2) expression
was increased. Urinary AQP2 was higher in nephrotic
individuals, matching histological findings (Wang et al.,
2015).
Endocrine Effects
Adrenalectomized, aldosterone-deficient rats with puromycin
aminonucleoside (PAN)-inducible nephrotic syndrome
with ascites have lower levels of apically expressed ENaC
in the collecting duct than non-adrenalectomized controls
(de Seigneux et al., 2006). This suggests that oedema
and nephrotic syndrome can occur in the absence of
aldosterone and aldosterone-dependent apical expression
of ENaC. Other endocrine and paracrine candidates
have been investigated in nephrotic animals to explain
aldosterone-independent sodium retention in nephrosis.
Inhibition of insulin like growth factor, tumor necrosis factor-
alpha, nitric oxide synthase in rat models did not induce
natriuresis, implying that these are not involved (Doucet et al.,
2007).
Angiotensin II is known to have a direct effect on
sodium retention independent of glomerular filtration rate
and aldosterone secretion (Johnson and Malvin, 1977; Miura
et al., 2014). Microperfusion of angiotensin II in distal nephron
segments of rat kidney stimulated transporter-like and channel-
like sodium retention (Wang and Giebisch, 1996).
The role of circulating factors on sodium retention are difficult
to predict as models of animal unilateral nephrosis demonstrate
only alterations in sodium handling in the affected kidney
(Doucet et al., 2007). The main determinant of sodium retention
is the Na+,K+-ATPase pump (discussed above) and the capillary
epithelial dysfunction.
Atrial natriuretic peptide stimulates sodium and water
excretion from the inner medullary collecting duct thereby
opposing the interstitial volume expansion (Baxter et al., 1988;
Light et al., 1989). After prolonged exposure to ANP there is
an increase in apical expression of aquaporin-2 and the gamma
subunit of ENaC (Wang et al., 2006). However, systemic infusion
of synthetic ANP or ANP extract in experimental studies in
nephrotic individuals had a diminished natriuretic and diuretic
response compared to healthy controls (Koepke and DiBona,
1987; Perico et al., 1989) despite the prediction from animal
models for the opposite (Wang et al., 2006).
Regardless of elevated serum ANP concentration in nephrotic
syndrome, natriuresis is blunted (Perico et al., 1989). This may
be due to increased activity of renal sympathetic nerves that
override the ANP response and stimulate sodium retention,
although denervated kidneys still demonstrate the same effect
(Maack, 1980). Alternatively, dysfunctional ANP binding in the
kidney may explain the relative renal resistance to ANP. In a
murine model of nephrotic syndrome, renal resistance to ANP
is reversed by phosphodiesterase inhibitors, implying that this
ANP resistance is mediated through enhanced cyclic GMP–
phosphodiesterase activity (Valentin et al., 1992).
The PPIL gene encoding cyclophilin-like protein is
upregulated in the medulla from nephrotic rats compared
with healthy control rat medullas (Orisio et al., 1993). The gene
product cyclophilin-like protein reduces sodium excretion (Iwai
and Inagami, 1990). ANP infusion increases the cyclophilin-like
protein mRNA in the renal medulla in nephrotic rats, so this
may be a potential mechanism of ANP insensitivity in nephrosis
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(Orisio et al., 1993). Down-regulation of the protease corin in
kidneys reduces conversion of pro-ANP to active ANP, also
contributing to a lack of renal response to ANP (Polzin et al.,
2010).
EPITHELIAL SODIUM CHANNEL
The ENaC mediates absorption of sodium in the late distal
convoluted tubule, connecting segment and tubule and the
collecting duct (Garty and Palmer, 1997). ENaC is activated by
aldosterone, anti-diuretic hormone and specific proteases (Garty
and Palmer, 1997; Kleyman et al., 2009; Rossier and Stutts, 2009;
Passero et al., 2010). The role of peroxisome proliferator activated
receptors oedema and ENaC remains unclear and is reviewed in
Pavlov et al. (2010). ENaC is composed of three subunits: alpha,
beta and gamma (Firsov et al., 1998). Proteases activate ENaC
by cleaving the alpha and gamma subunits (Hughey et al., 2003).
Dual cleavage of the gamma subunit renders ENaC highly active
(Sheng et al., 2006). Further, animal and human nephrotic urine
activates ENaC; proteases (e.g., plasmin) in the urine activate
and inhibitors of plasmin deactivate ENaC dependent sodium
currents in Xenopus laevis oocytes (Svenningsen et al., 2009).
Furthermore, remission of nephrotic syndrome is associated
with a reduction in urinary plasmin levels in patients’ urine.
Patients’ urine was applied to M1 collecting duct cells expressing
ENaC and there was a lower ability to activate ENaC-mediated
(amiloride sensitive) sodium currents compared to urine from
nephrotic patients (Andersen et al., 2013).
Most recently, a cohort study reports urinary plasmin
increases the risk of hypertension in type 1 diabetics.
Despite this association, the increased risk was dependent
on albuminuria and nor were there differences in urinary sodium
or potassium excretion. This was attributed to uncontrolled
patient sodium intake and urinary plasminogen deactivating
ENaC simultaneously (Ray et al., 2018).
Recent studies in mice using pharmacological inhibitors of
protease activity to inhibit the gamma subunit cleavage and
activation of ENaC have been successful at preventing sodium
retention. Urinary protease inhibitors normalized protease
activity and reduced sodium retention (Bohnert et al., 2018). Rats
with induced nephrotic syndrome had higher levels of urinary
plasminogen activator, and amiloride reduced this and sodium
retention without altering proteinuria (Stæhr et al., 2015).
Protease inhibition might be an attractive therapeutic option
in addition to ENaC antagonism (e.g., with amiloride). Protease
inhibition would occur before glomerular filtration, and therefore
its effectiveness would not be limited by the glomerular filtration
rate, unlike diuretics which act on the tubular epithelium after
filtration. Further, while the onset of action of a putative
protease inhibitor will be slower than ENaC antagonism, as it
depends on the rate of ENaC retrieval to the apical membrane
(Gaillard et al., 2010), the effect is likely to be sustained
rather than the short action of ENaC antagonism. Avid sodium
retention in between periods of action of diuretics has long
been observed (Wilcox et al., 1983; Loon et al., 1989), and is an
important contributor to diuretic resistance. Protease inhibition
may therefore present an intriguing route to ameliorate diuretic
resistance in nephrotic syndrome.
In animal models of nephrotic syndrome amiloride
successfully abolishes the abnormally high sodium reabsorption
from the cortical collecting duct independent of aldosterone
activity (Deschênes et al., 2001b, 2003). ENaC inhibitors
(amiloride) are not without side effects; they increase serum
potassium (Brown et al., 2016) and pose a risk of hyperkalemia so
should be used with caution in advanced chronic kidney disease
(Wile, 2012) or diabetic patients (Unruh et al., 2017). When
used in combination with other medications such as RAAS
blockers and diuretics the risk of acute kidney injury is higher
(Unruh et al., 2017; Hinrichs et al., 2018; Ray, 2018). There is
also an association with pressure ulcers in hospitalized patients
on amiloride (Roustit et al., 2016). There are other potential
downstream effects of amiloride. Amiloride inhibits urokinase
plasminogen activator and reduces plasmin generation (Vassalli
and Belin, 1987). Plasmin is pro-fibrotic (Zhang et al., 2007)
and therefore amiloride may potentially affect renal fibrosis.
Additionally, podocyte anchoring to the glomerular basement
membrane is affected by amiloride in experimental animal
studies and thereby could influence proteinuria (Zhang et al.,
2012; Reiser, 2013; Trimarchi et al., 2014; Warnock, 2015).
Epithelial sodium channel knockout mice exhibited
downregulation of the sodium chloride cotransporter (NCC)
which was then unable to compensate with the usual enhanced
compensatory sodium reabsorption (Perrier et al., 2016). NCC
can be phosphorylated and regulated by the serum potassium
concentration (Czogalla et al., 2016; Terker et al., 2016). Reduced
ENaC activity induces hyperkalemia which may be a more
important regulator of NCC than sodium balance (Boscardin
et al., 2018). It is possible that amiloride may mediate a degree of
NCC inhibition by increasing the serum potassium.
Combination treatments with amiloride have been trialed.
Amiloride causes a significant diuresis in mouse models treated
with acetazolamide (Patel-Chamberlin et al., 2016). Amiloride
and hydrochlorothiazide improved weight loss compared to
placebo in a population aged over 65 (Damian et al., 2016). The
addition of amiloride to RAAS blockers and hydrochlorothiazide,
improved proteinuria reduction by an additional 14% (Morales
et al., 2015). Despite the growing evidence for ENaC inhibition,
loop diuretics remain the mainstay of treatment.
We have focused on the putative mechanisms of salt and
water retention in nephrotic syndrome; however, mechanisms
other than renal sodium retention may be important in causing
interstitial oedema.
TREATMENT OF OEDEMA
Diuretics
We refer the reader to the review of Wile for details on the
history of diuretics (Wile, 2012). All classes of diuretics act
within the kidney to reduce renal tubular sodium reabsorption,
limiting water reabsorption with resulting diuresis. Diuretics
are classed as osmotic diuretics, carbonic anhydrase inhibitors,
loop, thiazide or potassium-sparing diuretics (The National
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Institute for Health and Care [NICE], 2018). All diuretics (with
the exception of mineralocorticoid receptor antagonists) act
on the luminal side of the tubular epithelium and need to
attain sufficient concentration to have an action there (Wile,
2012).
Loop diuretics (e.g., furosemide and bumetanide) work by
inhibiting the Na+-K+-2Cl− cotransporter, NKCC2 on the apical
surface in the thick ascending limb (TAL) in the loop of Henle
(Brater, 1991). This transporter reabsorbs sodium (Na+) in to
the tubular cell which is reclaimed to the circulation by the
Na+,K+-ATPase pump in the basolateral membrane (Brater,
1991). The TAL is the site of approximately 25% of total sodium
reabsorption in the nephron, so loop diuretics are particularly
potent natriuretics (Burg, 1982).
Loop diuretics are highly protein bound and are secreted in
to the lumen by organic anion transporters along the proximal
tubule to reach their site of action in the TAL (Brater, 1991).
Gut oedema may limit the oral absorption of diuretics and
hypoalbuminemia decreases the delivery of diuretic to its site of
action (Sica, 2003). For this reason higher doses may be required
to achieve a successful diuresis, although with a higher likelihood
of adverse effects (Crew et al., 2004). Intravenous infusion is
another approach that can increase loop diuretic efficacy as
therapeutic levels are achieved rapidly due to lower absorption
time (Hammarlund et al., 1984).
Furosemide has incomplete and variable bioavailability
even in healthy individuals (Waller et al., 1981); probably
the worst in its class, despite its widespread popularity.
Furosemide has both poor aqueous solubility and low intestinal
permeability, and oral furosemide bioavailability varies greatly
(by an estimated 20–60%) both between individuals and within
individuals (Granero et al., 2010; Nielsen et al., 2016). In the
oedematous state bioavailability is further reduced (e.g., to 30%)
(Odlind and Beermann, 1980). There is current work using
nanoparticles or polymeric microcontainers aiming to stabilize
and reduce this effect (Sahu and Das, 2014; Nielsen et al.,
2016).
Any diuretics can cause hypovolemia with secondary
acute kidney injury (Crew et al., 2004; Oh and Han,
2015). Electrolyte dysregulation is frequent; including
hypokalemia, hypomagnesemia, hypocalcemia, hyponatremia,
and hyperuricemia. This requires monitoring. Moreover,
furosemide can cause hypersensitivity reactions such as skin
rashes or acute interstitial nephritis (Oh and Han, 2015). There
is a risk of reversible ototoxicity related to the peak serum drug
concentration due to the ubiquitous NKCC1 present in the inner
ear also being inhibited with loop diuretic use (Wile, 2012).
Diuretics can displace warfarin from its protein binding site,
increasing the anti-coagulant effect (Oh and Han, 2015). This
is seen with furosemide (Oh and Han, 2015) and the active
metabolite (canrenone) of spironolactone (Takamura et al.,
1997).
Novel Agents
Vasopressin receptor antagonists (e.g., tolvaptan) are not
diuretics, but rather aquaretics. These drugs reduce the density of
luminal aquaporins to increase urinary water excretion without
natriuresis (The National Institute for Health and Care [NICE],
2018). To date there are three case reports on four individuals
describing the use of tolvaptan in massive oedema in nephrotic
individuals, with treatment described as successful in three out of
four cases (Shimizu et al., 2014; Park et al., 2015; Tanaka et al.,
2017).
Phase I trials have been completed for a novel particulate-
guanylyl-cyclase A receptor activator (trial name ZD100) that
promotes natriuresis, inhibits aldosterone and reduced blood
pressure with activation of cyclic guanosine monophosphate
(Chen et al., 2016). At present this is being investigated in the
use of resistant hypertension but if it has natriuretic properties it
may be suitable for use in oedema in nephrosis.
Relaxin, an endogenous neurohormone is currently being
trialed in heart failure and has completed phase III trials
(Wilson et al., 2015). Relaxin induces increased expression of
both epithelial and endothelial endothelin B receptor (ETB) and
thereby indirectly stimulates ETB (Garvin and Sanders, 1991;
Danielson et al., 2000; Bogzil et al., 2005; Schneider et al.,
2007). ETB inhibits Na+,K+-ATPase and ADH causing both
a natriuresis and diuresis (Garvin and Sanders, 1991). The
fractional increase in urinary excretion of sodium occurs without
any changes in aldosterone or ANP concentrations (Bogzil et al.,
2005). In heart failure, treated individuals were found to require
lower doses of loop diuretics, had greater weight loss and reduced
signs and symptoms of fluid overload including peripheral and
pulmonary oedema (Metra et al., 2013; Voors et al., 2014).
However, this has had no effect on overall outcomes (Teerlink,
2017; Teerlink et al., 2017), and nor is it known if the endothelin
dysregulation in heart failure is present in nephrosis.
There have been two cases from a single center in Japan of
synthetic human ANP (carperitide) reducing interstitial oedema
preventing the need for hemodialysis and preserving renal
function in nephrotic patients (Ueda et al., 2014).
Luteolin is a common phenolic compound known
to have anti-inflammatory and anti-allergic effects. Rat
studies have recently demonstrated the role of luteolin in
natriuresis and diuresis with an additive effect achieved
with administration of amiloride and hydrochlorothiazide
(Boeing et al., 2017). Luteolin mediated these effects via the
muscarinic acetylcholine receptor (Boeing et al., 2017). It
will be interesting to see if this has a similar role to play in
humans.
Most recently, the role of epicatechin was investigated.
Epicatechin is a flavonoid found in food and plant
extracts and is classed as a phytochemical (Mariano et al.,
2018). Rats treated with epicatechin achieved diuresis
and uresis of sodium, potassium and chloride without
any effect on the plasma electrolyte function (Mariano
et al., 2018). Combination with hydrochlorothiazide
further improved the diuretic effect (Mariano et al.,
2018).
Clinical Practice
There are no adult guidelines available on managing oedema
and volume overload in nephrotic syndrome (Crew et al.,
2004; Oh and Han, 2015). The lack of guidelines means
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that there is considerable heterogeneity in the treatment of
overloaded nephrotic individuals with no clear consensus. Non-
pharmacological interventions such as strict dietary sodium
restriction (less than 3g per day) are important and have
an additive effect to other therapies (Hull and Goldsmith,
2008). Replacing serum albumin with intravenous infusions to
improve the efficacy of loop diuretics has been investigated
considerably. This is because only albumin-bound loop diuretics
are secreted into the lumen of the tubule, discussed above.
Hypoalbuminemia (as is present in nephrotic syndrome) reduces
the amount of loop diuretics that are delivered to their
site of action in the tubular lumen (Kirchner et al., 1990;
Fliser et al., 1999). Albumin may help overcome this by
enhancing proximal tubular secretion to the tubular lumen
and reducing the volume of distribution (Inoue et al., 1987;
Chalasani et al., 2001). Early reports were encouraging with
massive diuresis when combined with diuretics (27 kg in
14 days) (Davison et al., 1974). Later studies demonstrate
conflicting results with better results in animal models and
minimal response in humans. There was little or no effect
on urinary furosemide or sodium excretion, despite elevated
serum albumin levels (Akcicek et al., 1995; Fliser et al., 1999;
Chalasani et al., 2001). Nor did inhibiting urinary protein
binding have any effect of furosemide efficacy (Agarwal et al.,
2000). Different mechanisms may exist in children as there has
been a successful response with co-administration of albumin
in some instances (Haws and Baum, 1993). Yet, the rate of
complications remains higher in pediatric patients with 38%
developing hypertension (Dorhout Mees, 1996). We refer the
reader to table 1 in the following review for a full synopsis
on all clinical trials with albumin and furosemide (Duffy et al.,
2015).
A multicenter retrospective study of 60 pediatric units
in Italy found no consensus approach to diuretic treatment
(Pasini et al., 2015). Despite similar laboratory and clinical
data across 231 children, 64% were treated with diuretics and
55% were treated with albumin infusions, highlighting the
treatment variability (Pasini et al., 2015). The authors suggest that
shared guidelines and implementation were necessary to avoid
differences and side effects in pediatric patients (Pasini et al.,
2015).
In adults, there is also no consensus on the indication,
starting dose, approach to dosage change and monitoring of
diuretics; consequently, there are considerable differences in
treatment pathways. In general, standard first line treatment
is a loop diuretic such as furosemide (Crew et al., 2004).
The diuretic would normally be started at a low dose and
then sequentially increased until satisfactory weight loss
or until the maximum dose has been reached. If at this
stage the patient remains symptomatic, a second, synergetic
diuretic is commonly added. In the United Kingdom, this
would usually be the thiazide-like metolazone (Crew et al.,
2004). This is not always successful and a recent case
report described resistance to the loop and thiazide type
diuretic combination in a oedematous nephrotic patient.
The oedema instead responded well to a combination of
furosemide and an ENaC inhibitor (triamterene) (Hoorn and
Ellison, 2017). Another case report describes a treatment
resistant nephrotic patient with no diuretic effect after
5 weeks of high dose furosemide but a profound 7 kg
fluid loss with the addition of amiloride (Hinrichs et al.,
2018). While these are only two case reports they provide
further evidence to support ENaC blockade as effective
treatment of nephrotic oedema, although larger studies will be
necessary.
There are no trials directly comparing the commonly
used different diuretic regimens in nephrotic syndrome
despite the underlying scientific basis of causation for
oedema in animal models. Furosemide remains first line
treatment yet has extremely variable oral bioavailability
and the problematic well-described blunted natriuretic
effect with prolonged therapy (Bernstein and Ellison,
2011).
More recently, a randomized controlled study in
Iran compared different diuretic pre-loading regimens
in 20 individuals with refractory nephrosis. The two
arms were either pre-loading with acetazolamide and
hydrochlorothiazide compared to pre-loading with
furosemide and hydrochlorothiazide for 1 week after
which both treatment arms received 2 weeks of 40 mg
furosemide. Patients with hypokalemia were excluded
in view of the potassium wasting properties of these
diuretics. The authors concluded that the acetazolamide
and hydrochlorothiazide combination achieved a better
diuresis. While there was a difference in the mean weight
change and urinary volume there was no difference in
the urinary sodium and hence natriuresis over the trial
period (Fallahzadeh et al., 2017). We discussed above that
this was successful in animal models (Patel-Chamberlin
et al., 2016). Inhibition of pendrin which is found in the
collecting duct is part of a proposed route of sodium
reabsorption in the collecting duct with acetazolamide
(Zahedi et al., 2013). This may be another mechanism for
the synergistic effect with a loop diuretic (Soleimani et al.,
2012).
CONCLUSION
Patients and clinicians deserve better and more structured
information on how to successfully manage nephrotic
oedema. With increased understanding of the underlying
pathophysiology of interstitial oedema in nephrotic syndrome
we are in a better position to better treat individuals suffering
with the complications that severe interstitial oedema
brings. Management of oedema in nephrotic syndrome
will rely on individualization of therapy with consideration
of the clinical evidence. Differences especially will exist
in the treatment between pediatric and adult patients
and it is likely that there is no one best treatment for
everyone. It will be helpful to understand determinants
of response to treatment. Based on the evidence we
provide in the review we especially advocate clinical trials
to investigate the potential benefits of ENaC blockade.
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For example, it may be important in certain types of drug-
induced oedema, such as that seen with thiazolidinediones,which
stimulate ENaC-mediated sodium reabsorption through PPARγ
receptors (Guan et al., 2005). We hope that with appropriately
designed trials, guidelines can be developed based on robust
clinical evidence to achieve improved outcomes.
AUTHOR CONTRIBUTIONS
SG drafted the manuscript with critical revision by RJP, NA, and
SBW.
FUNDING
SG has received funding from UCB for her Ph.D.
ACKNOWLEDGMENTS
We would like to acknowledge the support from the UCL
Centre for Nephrology to SBW, RJP, and SG. The support from
the glomerular disease group at Barts Health for NA and SG.
Additionally SG, RJP, NA, and SBW are grateful to their ongoing
collaborations with the London Membranous Network.
REFERENCES
Agarwal, R., Gorski, J. C., Sundblad, K., and Brater, D. C. (2000). Urinary protein
binding does not affect response to furosemide in patients with nephrotic
syndrome. J. Am. Soc. Nephrol. 11, 1100–1105.
Akcicek, F., Yalniz, T., Basci, A., Ok, E., and Mees, E. J. D. (1995). Diuretic effect of
frusemide in patients with nephrotic syndrome: is it potentiated by intravenous
albumin? BMJ 310, 162–163. doi: 10.1136/bmj.310.6973.162
Andersen, R. F., Buhl, K. B., Jensen, B. L., Svenningsen, P., Friis, U. G., Jespersen, B.,
et al. (2013). Remission of nephrotic syndrome diminishes urinary plasmin
content and abolishes activation of ENaC. Pediatr. Nephrol. 28, 1227–1234.
doi: 10.1007/s00467-013-2439-2
Bates, D. O. (2010). Vascular endothelial growth factors and vascular permeability.
Cardiovasc. Res. 87, 262–271. doi: 10.1093/cvr/cvq105
Bauer, J. H. (1983). Effects of propranolol therapy on renal function and body
fluid composition. Arch. Intern. Med. 143, 927–931. doi: 10.1001/archinte.1983.
00350050085016
Baxter, J. D., Lewicki, J. A., and Gardner, D. G. (1988). Atrial natriuretic peptide.
Nat. Biotechnol. 6, 529–546. doi: 10.1038/nbt0588-529
Beanlands, H., Maione, M., Poulton, C., Herreshoff, E., Hladunewich, M. A.,
Hailperin, M., et al. (2017). Learning to live with nephrotic syndrome:
experiences of adult patients and parents of children with nephrotic syndrome.
Nephrol. Dial. Transplant. 32, i98–i105. doi: 10.1093/ndt/gfw344
Bernstein, P. L., and Ellison, D. H. (2011). Diuretics and salt transport along the
nephron. Semin. Nephrol. 31, 475–482. doi: 10.1016/j.semnephrol.2011.09.002
Besse-Eschmann, V., Klisic, J., Nief, V., Hir, M. L., Kaissling, B., and Ambühl, P. M.
(2002). Regulation of the proximal tubular sodium/proton exchanger NHE3
in rats with puromycin aminonucleoside (PAN)-induced nephrotic syndrome.
J. Am. Soc. Nephrol. 13, 2199–2206. doi: 10.1097/01.ASN.0000028839.52271.DF
Boeing, T., da Silva, L. M., Mariott, M., Andrade, S. F., and de Souza, P. (2017).
Diuretic and natriuretic effect of luteolin in normotensive and hypertensive
rats: role of muscarinic acetylcholine receptors. Pharmacol. Rep. 69, 1121–1124.
doi: 10.1016/j.pharep.2017.05.010
Bogzil, A. H., Eardley, R., and Ashton, N. (2005). Relaxin-induced changes in renal
sodium excretion in the anesthetized male rat. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 288, R322–R328. doi: 10.1152/ajpregu.00509.2004
Bohnert, B. N., Menacher, M., Janessa, A., Wörn, M., Schork, A., Daiminger, S.,
et al. (2018). Aprotinin prevents proteolytic epithelial sodium channel (ENaC)
activation and volume retention in nephrotic syndrome. Kidney Int. 93, 159–
172. doi: 10.1016/j.kint.2017.07.023
Boscardin, E., Perrier, R., Sergi, C., Maillard, M. P., Loffing, J., Loffing-Cueni, D.,
et al. (2018). Plasma potassium determines NCC abundance in adult kidney-
specific γ ENaC knockout. J. Am. Soc. Nephrol. 29, 977–990. doi: 10.1681/ASN.
2017030345
Brater, D. C. (1991). Clinical pharmacology of loop diuretics. Drugs 41, 14–22.
doi: 10.2165/00003495-199100413-00004
Brown, E., Markandu, N., Sagnella, G., Jones, B., and MacGregor, G. (1984). Lack of
effect of captopril on the sodium retention of the nephrotic syndrome. Nephron
37, 43–48. doi: 10.1159/000183206
Brown, M. J., Williams, B., Morant, S. V., Webb, D. J., Caulfield, M. J.,
Cruickshank, J. K., et al. (2016). Effect of amiloride, or amiloride plus
hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and
blood pressure (PATHWAY-3): a parallel-group, double-blind randomised
phase 4 trial. Lancet Diabetes Endocrinol. 4, 136–147. doi: 10.1016/S2213-
8587(15)00377-0
Burg, M. B. (1982). Thick ascending limb of Henle’s loop. Kidney Int. 22, 454–464.
doi: 10.1038/ki.1982.198
Byku, M., and Mann, D. L. (2017). “Chapter 19 - Neuromodulation of
the failing heart,” in Cardioskeletal Myopathies in Children and Young
Adults, eds J. L. Jefferies, B. C. Blaxall, J. Robbins, and J. A. Towbin
(Boston, MA: Academic Press), 381–397. doi: 10.1016/B978-0-12-800040-3.
00019-4
Cadnapaphornchai, M. A., Tkachenko, O., Shchekochikhin, D., and Schrier,
R. W. (2014). The nephrotic syndrome: pathogenesis and treatment of edema
formation and secondary complications. Pediatr. Nephrol. 29, 1159–1167. doi:
10.1007/s00467-013-2567-8
Chalasani, N., Gorski, J. C., Horlander, J. C., Craven, R., Hoen, H., Maya, J., et al.
(2001). Effects of albumin/furosemide mixtures on responses to furosemide in
hypoalbuminemic patients. J. Am. Soc. Nephrol. 12, 1010–1016.
Chen, H. H., Neutel, J. M., Smith, D. H., Heublein, D., and Burnett, J. C.
(2016). A first-in-human trial of a novel designer natriuretic peptide ZD100
in human hypertension. J. Am. Soc. Hypertens. 10:e23. doi: 10.1016/j.jash.2016.
03.051
Crew, R. J., Radhakrishnan, J., and Appel, G. (2004). Complications of the
nephrotic syndrome and their treatment. Clin. Nephrol. 62, 245–259. doi: 10.
5414/CNP62245
Czogalla, J., Vohra, T., Penton, D., Kirschmann, M., Craigie, E., and Loffing, J.
(2016). The mineralocorticoid receptor (MR) regulates ENaC but not NCC
in mice with random MR deletion. Pflügers Arch. 468, 849–858. doi: 10.1007/
s00424-016-1798-5
Damian, D. J., McNamee, R., and Carr, M. (2016). Changes in selected metabolic
parameters in patients over 65 receiving hydrochlorothiazide plus amiloride,
atenolol or placebo in the MRC elderly trial. BMC Cardiovasc. Disord. 16:188.
doi: 10.1186/s12872-016-0368-2
Danielson, L. A., Kercher, L. J., and Conrad, K. P. (2000). Impact of gender and
endothelin on renal vasodilation and hyperfiltration induced by relaxin in
conscious rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1298–R1304.
doi: 10.1152/ajpregu.2000.279.4.R1298
Davison, A. M., Lambie, A. T., Verth, A. H., and Cash, J. D. (1974). Salt-poor
human albumin in management of nephrotic syndrome. Br. Med. J. 1, 481–484.
doi: 10.1136/bmj.1.5906.481
de Seigneux, S., Kim, S. W., Hemmingsen, S. C., Frøkiær, J., and Nielsen, S.
(2006). Increased expression but not targeting of ENaC in adrenalectomized
rats with PAN-induced nephrotic syndrome. Am. J. Physiol. Renal Physiol. 291,
F208–F217. doi: 10.1152/ajprenal.00399.2005
Deschênes, G., and Doucet, A. (2000). Collecting duct Na+/K+-ATPase activity is
correlated with urinary sodium excretion in rat nephrotic syndromes. J. Am.
Soc. Nephrol. 11, 604–615.
Deschênes, G., Feraille, E., and Doucet, A. (2003). Mechanisms of oedema in
nephrotic syndrome: old theories and new ideas. Nephrol. Dial. Transplant. 18,
454–456. doi: 10.1093/ndt/18.3.454
Deschênes, G., Gonin, S., Zolty, E., Cheval, L., Rousselot, M., Martin, P.-Y., et al.
(2001a). Increased synthesis and AVP unresponsiveness of Na,K-ATPase in
collecting duct from nephrotic rats. J. Am. Soc. Nephrol. 12, 2241–2252.
Frontiers in Physiology | www.frontiersin.org 7 January 2019 | Volume 9 | Article 1868
fphys-09-01868 January 14, 2019 Time: 16:37 # 8
Gupta et al. Nephrotic Oedema and Diuretics
Deschênes, G., Wittner, M., Stefano, A. D., Jounier, S., and Doucet, A. (2001b).
Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for
amiloride therapy. J. Am. Soc. Nephrol. 12, 598–601.
Dorhout Mees, E. J. (1996). Does it make sense to administer albumin to the
patient with nephrotic oedema? Nephrol. Dial. Transplant. 11, 1224–1226. doi:
10.1093/ndt/11.7.1224
Doucet, A., Favre, G., and Deschênes, G. (2007). Molecular mechanism of edema
formation in nephrotic syndrome: therapeutic implications. Pediatr. Nephrol.
22, 1983–1990. doi: 10.1007/s00467-007-0521-3
Duffy, M., Jain, S., Harrell, N., Kothari, N., and Reddi, A. S. (2015). Albumin and
furosemide combination for management of edema in nephrotic syndrome: a
review of clinical studies. Cells 4, 622–630. doi: 10.3390/cells4040622
Ellis, D. (2016). Pathophysiology, evaluation, and management of edema in
childhood nephrotic syndrome. Front. Pediatr. 3:111. doi: 10.3389/fped.2015.
00111
Fallahzadeh, M. A., Dormanesh, B., Fallahzadeh, M. K., Roozbeh, J., Fallahzadeh,
M. H., and Sagheb, M. M. (2017). Acetazolamide and hydrochlorothiazide
followed by furosemide versus furosemide and hydrochlorothiazide followed
by furosemide for the treatment of adults with nephrotic edema: a randomized
trial. Am. J. Kidney Dis. 69, 420–427. doi: 10.1053/j.ajkd.2016.10.022
Farquhar, M. G., and Palade, G. E. (1961). Glomerular permeability: II. Ferritin
transfer across the glomerular capillary wall in nephrotic rats. J. Exp. Med. 114,
699–716. doi: 10.1084/jem.114.5.699
Féraille, E., Vogt, B., Rousselot, M., Barlet-Bas, C., Cheval, L., Doucet, A., et al.
(1993). Mechanism of enhanced Na-K-ATPase activity in cortical collecting
duct from rats with nephrotic syndrome. J. Clin. Invest. 91, 1295–1300. doi:
10.1172/JCI116328
Firsov, D., Gautschi, I., Merillat, A.-M., Rossier, B. C., and Schild, L. (1998). The
heterotetrameric architecture of the epithelial sodium channel (ENaC). EMBO
J. 17, 344–352. doi: 10.1093/emboj/17.2.344
Fliser, D., Zurbrüggen, I., Mutschler, E., Bischoff, I., Nussberger, J., Franek, E.,
et al. (1999). Coadministration of albumin and furosemide in patients with the
nephrotic syndrome. Kidney Int. 55, 629–634. doi: 10.1046/j.1523-1755.1999.
00298.x
Fodor, P., Saitúa, M. T., Rodriguez, E., González, B., and Schlesinger, L. (1982).
T-cell dysfunction in minimal-change nephrotic syndrome of childhood. Am. J.
Dis. Child. 136, 713–717. doi: 10.1001/archpedi.1982.03970440057016
Gaillard, E. A., Kota, P., Gentzsch, M., Dokholyan, N. V., Stutts, M. J., and
Tarran, R. (2010). Regulation of the epithelial Na+ channel and airway surface
liquid volume by serine proteases. Pflugers Arch. 460, 1–17. doi: 10.1007/
s00424-010-0827-z
Garty, H., and Palmer, L. G. (1997). Epithelial sodium channels: function, structure,
and regulation. Physiol. Rev. 77, 359–396. doi: 10.1152/physrev.1997.77.2.359
Garvin, J., and Sanders, K. (1991). Endothelin inhibits fluid and bicarbonate
transport in part by reducing Na+/K+ ATPase activity in the rat proximal
straight tubule. J. Am. Soc. Nephrol. 2, 976–982.
Geers, A. B., Koomans, H. A., Boer, P., and Dorhout Mees, E. J. (1984). Plasma and
blood volumes in patients with the nephrotic syndrome. Nephron 38, 170–173.
doi: 10.1159/000183302
Granero, G. E., Longhi, M. R., Mora, M. J., Junginger, H. E., Midha, K. K., Shah,
V. P., et al. (2010). Biowaiver monographs for immediate release solid oral
dosage forms: furosemide. J. Pharm. Sci. 99, 2544–2556. doi: 10.1002/jps.22030
Guan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., et al. (2005).
Thiazolidinediones expand body fluid volume through PPARγ stimulation of
ENaC-mediated renal salt absorption. Nat. Med. 11, 861–866. doi: 10.1038/
nm1278
Hammarlund, M. M., Paalzow, L. K., and Odlind, B. (1984). Pharmacokinetics
of furosemide in man after intravenous and oral administration. Application
of moment analysis. Eur. J. Clin. Pharmacol. 26, 197–207. doi: 10.1007/
BF00630286
Haws, R. M., and Baum, M. (1993). Efficacy of albumin and diuretic therapy in
children with nephrotic syndrome. Pediatrics 91, 1142–1146.
Hinrichs, G. R., Mortensen, L. A., Jensen, B. L., and Bistrup, C. (2018).
Amiloride resolves resistant edema and hypertension in a patient with
nephrotic syndrome; a case report. Physiol. Rep. 6:e13743. doi: 10.14814/phy2.
13743
Hoorn, E. J., and Ellison, D. H. (2017). Diuretic resistance. Am. J. Kidney Dis. 69,
136–142. doi: 10.1053/j.ajkd.2016.08.027
Hughey, R. P., Mueller, G. M., Bruns, J. B., Kinlough, C. L., Poland, P. A.,
Harkleroad, K. L., et al. (2003). Maturation of the epithelial Na+ channel
involves proteolytic processing of the alpha- and gamma-subunits. J. Biol.
Chem. 278, 37073–37082. doi: 10.1074/jbc.M307003200
Hull, R. P., and Goldsmith, D. J. (2008). Nephrotic syndrome in adults. BMJ 336,
1185–1189. doi: 10.1136/bmj.39576.709711.80
Humphreys, M. H. (1994). Mechanisms and management of nephrotic edema.
Kidney Int. 45, 266–281. doi: 10.1038/ki.1994.33
Hung, S.-C., Kuo, K.-L., Peng, C.-H., Wu, C.-H., Lien, Y.-C., Wang, Y.-C., et al.
(2014). Volume overload correlates with cardiovascular risk factors in patients
with chronic kidney disease. Kidney Int. 85, 703–709. doi: 10.1038/ki.2013.336
Ichikawa, I., Rennke, H. G., Hoyer, J. R., Badr, K. F., Schor, N., Troy, J. L.,
et al. (1983). Role for intrarenal mechanisms in the impaired salt excretion
of experimental nephrotic syndrome. J. Clin. Invest. 71, 91–103. doi: 10.1172/
JCI110756
Inoue, M., Okajima, K., Itoh, K., Ando, Y., Watanabe, N., Yasaka, T., et al.
(1987). Mechanism of furosemide resistance in analbuminemic rats and
hypoalbuminemic patients. Kidney Int. 32, 198–203. doi: 10.1038/ki.1987.192
Iwai, N., and Inagami, T. (1990). Molecular cloning of a complementary DNA to
rat cyclophilin-like protein mRNA. Kidney Int. 37, 1460–1465. doi: 10.1038/ki.
1990.136
Johnson, M. D., and Malvin, R. L. (1977). Stimulation of renal sodium reabsorption
by angiotensin II. Am. J. Physiol. Renal Physiol. 232, F298–F306. doi: 10.1152/
ajprenal.1977.232.4.F298
Keenswijk, W., Ilias, M. I., Raes, A., Donckerwolcke, R., and Walle, J. V. (2018).
Urinary potassium to urinary potassium plus sodium ratio can accurately
identify hypovolemia in nephrotic syndrome: a provisional study. Eur. J.
Pediatr. 177, 79–84. doi: 10.1007/s00431-017-3029-2
Kim, S. W., de Seigneux, S., Sassen, M. C., Lee, J., Kim, J., Knepper, M. A.,
et al. (2006). Increased apical targeting of renal ENaC subunits and decreased
expression of 11βHSD2 in HgCl2-induced nephrotic syndrome in rats. Am. J.
Physiol. Renal Physiol. 290, F674–F687. doi: 10.1152/ajprenal.00084.2005
Kirchner, K. A., Voelker, J. R., and Brater, D. C. (1990). Intratubular albumin
blunts the response to furosemide-A mechanism for diuretic resistance in the
nephrotic syndrome. J. Pharmacol. Exp. Ther. 252, 1097–1101.
Kleyman, T. R., Carattino, M. D., and Hughey, R. P. (2009). ENaC at the cutting
edge: regulation of epithelial sodium channels by proteases. J. Biol. Chem. 284,
20447–20451. doi: 10.1074/jbc.R800083200
Klisic, J., Zhang, J., Nief, V., Reyes, L., Moe, O. W., and Ambühl, P. M. (2003).
Albumin regulates the Na+/H+ exchanger 3 in OKP cells. J. Am. Soc. Nephrol.
14, 3008–3016. doi: 10.1097/01.ASN.0000098700.70804.D3
Koepke, J. P., and DiBona, G. F. (1987). Blunted natriuresis to atrial natriuretic
peptide in chronic sodium-retaining disorders. Am. J. Physiol. 252, F865–F871.
doi: 10.1152/ajprenal.1987.252.5.F865
Koot, B. G. P., Houwen, R., Pot, D.-J., and Nauta, J. (2004). Congenital
analbuminaemia: biochemical and clinical implications. A case report and
literature review. Eur. J. Pediatr. 163, 664–670. doi: 10.1007/s00431-004-1492-z
Korbet, S. M., Genchi, R. M., Borok, R. Z., and Schwartz, M. M. (1996). The racial
prevalence of glomerular lesions in nephrotic adults. Am. J. Kidney Dis. 27,
647–651. doi: 10.1016/S0272-6386(96)90098-0
Kottke, M. A., and Walters, T. J. (2016). Where’s the leak in vascular barriers? A
review. Shock 46, 20–36. doi: 10.1097/SHK.0000000000000666
Lagrue, G., Branellec, A., Blanc, C., Xheneumont, S., Beaudoux, F., Sobel, A., et al.
(1975a). A vascular permeability factor in lymphocyte culture supernants from
patients with nephrotic syndrome. II. Pharmacological and physicochemical
properties. Biomed. Publiee Pour AAICIG 23, 73–75.
Lagrue, G., Xheneumont, S., Branellec, A., Hirbec, G., and Weil, B. (1975b).
A vascular permeability factor elaborated from lymphocytes. I. Demonstration
in patients with nephrotic syndrome. Biomedicine 23, 37–40.
Lewis, D. M., Tooke, J. E., Beaman, M., Gamble, J., and Shore, A. C. (1998).
Peripheral microvascular parameters in the nephrotic syndrome. Kidney Int.
54, 1261–1266. doi: 10.1046/j.1523-1755.1998.00100.x
Light, D. B., Schwiebert, E. M., Karlson, K. H., and Stanton, B. A. (1989). Atrial
natriuretic peptide inhibits a cation channel in renal inner medullary collecting
duct cells. Science 243, 383–385. doi: 10.1126/science.2463673
Loon, N. R., Wilcox, C. S., and Unwin, R. J. (1989). Mechanism of impaired
natriuretic response to furosemide during prolonged therapy. Kidney Int. 36,
682–689. doi: 10.1038/ki.1989.246
Frontiers in Physiology | www.frontiersin.org 8 January 2019 | Volume 9 | Article 1868
fphys-09-01868 January 14, 2019 Time: 16:37 # 9
Gupta et al. Nephrotic Oedema and Diuretics
Lourdel, S., Loffing, J., Favre, G., Paulais, M., Nissant, A., Fakitsas, P., et al. (2005).
Hyperaldosteronemia and activation of the epithelial sodium channel are not
required for sodium retention in puromycin-induced nephrosis. J. Am. Soc.
Nephrol. 16, 3642–3650. doi: 10.1681/ASN.2005040363
Maack, T. (1980). Physiological evaluation of the isolated perfused rat kidney. Am.
J. Physiol. 238, F71–F78. doi: 10.1152/ajprenal.1980.238.2.F71
Mariano, L. N. B., Boeing, T., da Silva, R. C. M. V. A. F., Cechinel-Filho, V.,
Niero, R., da Silva, L. M., et al. (2018). Preclinical evaluation of the diuretic
and saluretic effects of (-)-epicatechin and the result of its combination with
standard diuretics. Biomed. Pharmacother. 107, 520–525. doi: 10.1016/j.biopha.
2018.08.045
Marino, F., Martorano, C., Tripepi, R., Bellantoni, M., Tripepi, G., Mallamaci, F.,
et al. (2016). Subclinical pulmonary congestion is prevalent in nephrotic
syndrome. Kidney Int. 89, 421–428. doi: 10.1038/ki.2015.279
McGrogan, A., Franssen, C. F., and de Vries, C. S. (2011). The incidence of primary
glomerulonephritis worldwide: a systematic review of the literature. Nephrol.
Dial. Transplant. 26, 414–430. doi: 10.1093/ndt/gfq665
Meltzer, J. I., Keim, H. J., Laragh, J. H., Sealey, J. E., Jan, K. M., and Chien, S. (1979).
Nephrotic syndrome: vasoconstriction and hypervolemic types indicated by
renin-sodium profiling. Ann. Intern. Med. 91, 688–696. doi: 10.7326/0003-
4819-91-5-688
Mernissi, G. E., and Doucet, A. (1983). Short-term effect of aldosterone on renal
sodium transport and tubular Na-K-ATPase in the rat. Pflügers Arch. 399,
139–146. doi: 10.1007/BF00663910
Metra, M., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg,
B. H., et al. (2013). Effect of serelaxin on cardiac, renal, and hepatic biomarkers
in the Relaxin in Acute Heart Failure (RELAX-AHF) development program:
correlation with outcomes. J. Am. Coll. Cardiol. 61, 196–206. doi: 10.1016/j.jacc.
2012.11.005
Miura, T., Watanabe, S., Urushihara, M., Kobori, H., and Fukuda, M. (2014).
The natriuretic effect of angiotensin receptor blockers is not attributable to
blood pressure reduction during the previous night, but to inhibition of tubular
sodium reabsorption. J. Renin Angiotensin Aldosterone Syst. 15, 316–318. doi:
10.1177/1470320313518253
Morales, E., Caro, J., Gutierrez, E., Sevillano, A., Auñón, P., Fernandez, C.,
et al. (2015). Diverse diuretics regimens differentially enhance the
antialbuminuric effect of renin–angiotensin blockers in patients with
chronic kidney disease. Kidney Int. 88, 1434–1441. doi: 10.1038/ki.
2015.249
Nielsen, L. H., Melero, A., Keller, S. S., Jacobsen, J., Garrigues, T., Rades, T.,
et al. (2016). Polymeric microcontainers improve oral bioavailability
of furosemide. Int. J. Pharm. 504, 98–109. doi: 10.1016/j.ijpharm.2016.
03.050
Odlind, B. O., and Beermann, B. (1980). Diuretic resistance: reduced bioavailability
and effect of oral frusemide. Br. Med. J. 280:1577. doi: 10.1136/bmj.280.6231.
1577
Ogi, M., Yokoyama, H., Tomosugi, N., Hisada, Y., Ohta, S., Takaeda, M., et al.
(1994). Risk factors for infection and immunoglobulin replacement therapy in
adult nephrotic syndrome. Am. J. Kidney Dis. 24, 427–436. doi: 10.1016/S0272-
6386(12)80899-7
Oh, S. W., and Han, S. Y. (2015). Loop diuretics in clinical practice. Electrolytes
Blood Press. 13, 17–21. doi: 10.5049/EBP.2015.13.1.17
Orisio, S., Perico, N., Benatti, L., Longaretti, L., Amuchastegui, S., and Remuzzi, G.
(1993). Renal cyclophilin-like protein gene expression parallels changes in
sodium excretion in experimental nephrosis and is positively modulated by
atrial natriuretic peptide. J. Am. Soc. Nephrol. 3, 1710–1716.
Park, E.-S., Huh, Y., and Kim, G.-H. (2015). Is tolvaptan indicated for refractory
oedema in nephrotic syndrome? Nephrology 20, 103–106. doi: 10.1111/nep.
12348
Pasini, A., Aceto, G., Ammenti, A., Ardissino, G., Azzolina, V., Bettinelli, A.,
et al. (2015). Best practice guidelines for idiopathic nephrotic syndrome:
recommendations versus reality. Pediatr. Nephrol. 30, 91–101. doi: 10.1007/
s00467-014-2903-7
Paskhina, T. S., Polyantseva, L. R., Krinskaya, A. V., Yegorova, T. P., Nartikova,
V. P., and Levina, G. O. (1979). High concentrations of free kinins
and kinin system components in abdominal transudate of a patient with
nephrotic syndrome. Clin. Chim. Acta 97, 73–82. doi: 10.1016/0009-8981(79)
90026-3
Passero, C. J., Hughey, R. P., and Kleyman, T. R. (2010). New role for plasmin in
sodium homeostasis. Curr. Opin. Nephrol. Hypertens. 19, 13–19. doi: 10.1097/
MNH.0b013e3283330fb2
Patel-Chamberlin, M., Kia, M. V., Xu, J., Barone, S., Zahedi, K., and Soleimani, M.
(2016). The role of epithelial sodium channel ENaC and the apical Cl-/HCO3-
exchanger pendrin in compensatory salt reabsorption in the setting of Na-Cl
cotransporter (NCC) inactivation. PLoS One 11:e0150918. doi: 10.1371/journal.
pone.0150918
Pavlov, T. S., Imig, J. D., and Staruschenko, A. (2010). Regulation of ENaC-
mediated sodium reabsorption by peroxisome proliferator-activated receptors.
PPAR Res. 2010:703735. doi: 10.1155/2010/703735
Perico, N., Delaini, F., Lupini, C., Benigni, A., Galbusera, M., Boccardo, P., et al.
(1989). Blunted excretory response to atrial natriuretic peptide in experimental
nephrosis. Kidney Int. 36, 57–64. doi: 10.1038/ki.1989.161
Perico, N., and Remuzzi, G. (1993). Edema of the nephrotic syndrome: the role of
the atrial peptide system. Am. J. Kidney Dis. 22, 355–366. doi: 10.1016/S0272-
6386(12)70137-3
Perrier, R., Boscardin, E., Malsure, S., Sergi, C., Maillard, M. P., Loffing, J.,
et al. (2016). Severe salt–losing syndrome and hyperkalemia induced by adult
nephron–specific knockout of the epithelial sodium channel α-subunit. J. Am.
Soc. Nephrol. 27, 2309–2318. doi: 10.1681/ASN.2015020154
Polzin, D., Kaminski, H. J., Kastner, C., Wang, W., Krämer, S., Gambaryan, S., et al.
(2010). Decreased renal corin expression contributes to sodium retention in
proteinuric kidney diseases. Kidney Int. 78, 650–659. doi: 10.1038/ki.2010.197
Ray, E. C. (2018). ENaC blockade in proteinuria-associated extracellular fluid
volume overload – effective but risky. Physiol. Rep. 6:e13835. doi: 10.14814/
phy2.13835
Ray, E. C., Miller, R. G., Demko, J. E., Costacou, T., Kinlough, C. L., Demko, C. L.,
et al. (2018). Urinary plasmin(ogen) as a prognostic factor for hypertension.
Kidney Int. Rep. 3, 1434–1442. doi: 10.1016/j.ekir.2018.06.007
Ray, E. C., Rondon-Berrios, H., Boyd, C. R., and Kleyman, T. R. (2015). Sodium
retention and volume expansion in nephrotic syndrome: implications for
hypertension. Adv. Chronic Kidney Dis. 22, 179–184. doi: 10.1053/j.ackd.2014.
11.006
Reiser, J. (2013). Circulating permeability factor suPAR: from concept to discovery
to clinic. Trans. Am. Clin. Climatol. Assoc. 124, 133–138.
Rossier, B. C., and Stutts, M. J. (2009). Activation of the epithelial sodium channel
(ENaC) by serine proteases. Annu. Rev. Physiol. 71, 361–379. doi: 10.1146/
annurev.physiol.010908.163108
Rostoker, G., Behar, A., and Lagrue, G. (2000). Vascular hyperpermeability in
nephrotic edema. Nephron 85, 194–200. doi: 10.1159/000045661
Roustit, M., Genty, C., Lepelley, M., Blaise, S., Fromy, B., Cracowski, J.-L.,
et al. (2016). Amiloride treatment and increased risk of pressure ulcers in
hospitalized patients. Br. J. Clin. Pharmacol. 82, 1685–1687. doi: 10.1111/bcp.
13084
Sahu, B. P., and Das, M. K. (2014). Formulation, optimization, and in vitro/in vivo
evaluation of furosemide nanosuspension for enhancement of its oral
bioavailability. J. Nanoparticle Res. 16:2360. doi: 10.1007/s11051-014-2360-z
Savin, V. J., Sharma, M., Zhou, J., Genochi, D., Sharma, R., Srivastava, T., et al.
(2017). Multiple targets for novel therapy of FSGS associated with circulating
permeability factor. Biomed Res. Int. 2017:6232616. doi: 10.1155/2017/6232616
Schneider, M. P., Boesen, E. I., and Pollock, D. M. (2007). Contrasting actions
of endothelin ETA and ETB receptors in cardiovascular disease. Annu. Rev.
Pharmacol. Toxicol. 47, 731–759. doi: 10.1146/annurev.pharmtox.47.120505.
105134
Sheng, S., Carattino, M. D., Bruns, J. B., Hughey, R. P., and Kleyman, T. R.
(2006). Furin cleavage activates the epithelial Na+ channel by relieving Na+
self-inhibition. Am. J. Physiol. Renal Physiol. 290, F1488–F1496. doi: 10.1152/
ajprenal.00439.2005
Shimizu, M., Ishikawa, S., Yachi, Y., Muraoka, M., Tasaki, Y., Iwasaki, H., et al.
(2014). Tolvaptan therapy for massive edema in a patient with nephrotic
syndrome. Pediatr. Nephrol. 29, 915–917. doi: 10.1007/s00467-013-2687-1
Sica, D. A. (2003). Drug absorption in the management of congestive heart failure:
loop diuretics. Congest. Heart Fail. 9, 287–292. doi: 10.1111/j.1527-5299.2003.
02399.x
Siddall, E. C., and Radhakrishnan, J. (2012). The pathophysiology of edema
formation in the nephrotic syndrome. Kidney Int. 82, 635–642. doi: 10.1038/
ki.2012.180
Frontiers in Physiology | www.frontiersin.org 9 January 2019 | Volume 9 | Article 1868
fphys-09-01868 January 14, 2019 Time: 16:37 # 10
Gupta et al. Nephrotic Oedema and Diuretics
Soleimani, M., Barone, S., Xu, J., Shull, G. E., Siddiqui, F., Zahedi, K., et al. (2012).
Double knockout of pendrin and Na-Cl cotransporter (NCC) causes severe salt
wasting, volume depletion, and renal failure. Proc. Natl. Acad. Sci. U.S.A. 109,
13368–13373. doi: 10.1073/pnas.1202671109
Stæhr, M., Buhl, K. B., Andersen, R. F., Svenningsen, P., Nielsen, F., Hinrichs, G. R.,
et al. (2015). Aberrant glomerular filtration of urokinase-type plasminogen
activator in nephrotic syndrome leads to amiloride-sensitive plasminogen
activation in urine. Am. J. Physiol. Renal Physiol. 309, F235–F241. doi: 10.1152/
ajprenal.00138.2015
Svenningsen, P., Bistrup, C., Friis, U. G., Bertog, M., Haerteis, S., Krueger, B.,
et al. (2009). Plasmin in nephrotic urine activates the epithelial sodium channel.
J. Am. Soc. Nephrol. 20, 299–310. doi: 10.1681/ASN.2008040364
Takamura, N., Maruyama, T., Ahmed, S., Suenaga, A., and Otagiri, M. (1997).
Interactions of aldosterone antagonist diuretics with human serum proteins.
Pharm. Res. 14, 522–526. doi: 10.1023/A:1012168020545
Tanaka, A., Nakamura, T., Sato, E., Ueda, Y., and Node, K. (2017). Different
effects of tolvaptan in patients with idiopathic membranous nephropathy with
nephrotic syndrome. Intern. Med. 56, 191–196. doi: 10.2169/internalmedicine.
56.7539
Teerlink, J. R. (2017). RELAXin in Acute Heart Failure-2. Paris: ACC.
Teerlink, J. R., Voors, A. A., Ponikowski, P., Pang, P. S., Greenberg, B. H.,
Filippatos, G., et al. (2017). Serelaxin in addition to standard therapy in acute
heart failure: rationale and design of the RELAX-AHF-2 study. Eur. J. Heart
Fail. 19, 800–809. doi: 10.1002/ejhf.830
Terker, A. S., Zhang, C., Erspamer, K. J., Gamba, G., Yang, C.-L., and Ellison,
D. H. (2016). Unique chloride-sensing properties of WNK4 permit the distal
nephron to modulate potassium homeostasis. Kidney Int. 89, 127–134. doi:
10.1038/ki.2015.289
The National Institute for Health, and Care [NICE] (2018). BNF: British National
Formulary. London: NICE.
Trimarchi, H., Forrester, M., Lombi, F., Pomeranz, V., Raña, M. S., Karl, A.,
et al. (2014). Amiloride as an alternate adjuvant antiproteinuric agent in
fabry disease: the potential roles of plasmin and uPAR. Case Rep. Nephrol.
2014:854521. doi: 10.1155/2014/854521
Udwan, K., Brideau, G., Fila, M., Edwards, A., Vogt, B., and Doucet, A. (2016).
Oxidative stress and nuclear factor κB (NF-κB) increase peritoneal filtration
and contribute to ascites formation in nephrotic syndrome. J. Biol. Chem. 291,
11105–11113. doi: 10.1074/jbc.M116.724690
Ueda, K., Hirahashi, J., Seki, G., Tanaka, M., Kushida, N., Takeshima, Y., et al.
(2014). Successful treatment of acute kidney injury in patients with idiopathic
nephrotic syndrome using human atrial natriuretic Peptide. Intern. Med. 53,
865–869. doi: 10.2169/internalmedicine.53.1724
Unruh, M. L., Pankratz, V. S., Demko, J. E., Ray, E. C., Hughey, R. P., and Kleyman,
T. R. (2017). Trial of amiloride in type 2 diabetes with proteinuria. Kidney Int.
Rep. 2, 893–904. doi: 10.1016/j.ekir.2017.05.008
Valentin, J. P., Qiu, C., Muldowney, W. P., Ying, W. Z., Gardner, D. G., and
Humphreys, M. H. (1992). Cellular basis for blunted volume expansion
natriuresis in experimental nephrotic syndrome. J. Clin. Invest. 90, 1302–1312.
doi: 10.1172/JCI115995
Vassalli, J.-D., and Belin, D. (1987). Amiloride selectively inhibits the urokinase-
type plasminogen activator. FEBS Lett. 214, 187–191. doi: 10.1016/0014-
5793(87)80039-X
Voors, A. A., Davison, B. A., Teerlink, J. R., Felker, G. M., Cotter, G., Filippatos, G.,
et al. (2014). Diuretic response in patients with acute decompensated heart
failure: characteristics and clinical outcome—an analysis from RELAX-AHF.
Eur. J. Heart Fail. 16, 1230–1240. doi: 10.1002/ejhf.170
Waller, E. S., Hamilton, S. F., Massarella, J. W., Sharanevych, M. A., Smith,
R. V., Yakatan, G. J., et al. (1981). Disposition and absolute bioavailability of
furosemide in healthy males. J. Pharm. Sci. 71, 1105–1108. doi: 10.1002/jps.
2600711006
Wang, T., and Giebisch, G. (1996). Effects of angiotensin II on electrolyte transport
in the early and late distal tubule in rat kidney. Am. J. Physiol. Renal Physiol. 271,
F143–F149. doi: 10.1152/ajprenal.1996.271.1.F143
Wang, W., Li, C., Nejsum, L. N., Li, H., Kim, S. W., Kwon, T.-H., et al. (2006).
Biphasic effects of ANP infusion in conscious, euvolemic rats: roles of AQP2
and ENaC trafficking. Am. J. Physiol. Renal Physiol. 290, F530–F541.
Wang, Y., Bu, J., Zhang, Q., Chen, K., Zhang, J., and Bao, X. (2015). Expression
pattern of aquaporins in patients with primary nephrotic syndrome with edema.
Mol. Med. Rep. 12, 5625–5632. doi: 10.3892/mmr.2015.4209
Warnock, D. G. (2015). Amiloride: the “new” renal tonic? Am. J. Physiol. Renal
Physiol. 309, F429–F430. doi: 10.1152/ajprenal.00237.2015
Webb, N. J. A., Watson, C. J., Roberts, I. S., Bottomley, M. J., Jones,
C. A., Lewis, M. A., et al. (1999). Circulating vascular endothelial growth
factor is not increased during relapses of steroid-sensitive nephrotic
syndrome. Kidney Int. 55, 1063–1071. doi: 10.1046/j.1523-1755.1999.055003
1063.x
Wilcox, C. S., Mitch, W. E., Kelly, R. A., Skorecki, K., Meyer, T. W., Friedman, P. A.,
et al. (1983). Response of the kidney to furosemide: I. Effects of salt intake and
renal compensation. J. Lab. Clin. Med. 102, 450–458.
Wile, D. (2012). Diuretics: a review. Ann. Clin. Biochem. 49, 419–431. doi: 10.1258/
acb.2011.011281
Wilson, S. S., Ayaz, S. I., and Levy, P. D. (2015). Relaxin: a novel agent for the
treatment of acute heart failure. Pharmacother. J. Hum. Pharmacol. Drug Ther.
35, 315–327. doi: 10.1002/phar.1548
Zahedi, K., Barone, S., Xu, J., and Soleimani, M. (2013). Potentiation of the effect of
thiazide derivatives by carbonic anhydrase inhibitors: molecular mechanisms
and potential clinical implications. PLoS One 8:e79327. doi: 10.1371/journal.
pone.0079327
Zhang, B., Xie, S., Shi, W., and Yang, Y. (2012). Amiloride off-target effect inhibits
podocyte urokinase receptor expression and reduces proteinuria. Nephrol. Dial.
Transplant. 27, 1746–1755. doi: 10.1093/ndt/gfr612
Zhang, G., Kernan, K. A., Collins, S. J., Cai, X., López-Guisa, J. M.,
Degen, J. L., et al. (2007). Plasmin(ogen) promotes renal interstitial
fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-
activated signals. J. Am. Soc. Nephrol. 18, 846–859. doi: 10.1681/ASN.20060
80886
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Gupta, Pepper, Ashman and Walsh. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Physiology | www.frontiersin.org 10 January 2019 | Volume 9 | Article 1868
